Literature DB >> 7609055

Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus.

C Bogedain1, H Wolf, S Modrow, G Stuber, W Jilg.   

Abstract

We identified the immediate-early transactivator Zta of Epstein-Barr virus as a target for specific cytotoxic T lymphocytes (CTL). Cells pulsed with overlapping synthetic peptides representing the entire amino acid sequence of Zta proved to be efficient for the in vitro stimulation of Zta-specific CTL in several donors. With peptide-pulsed target cells, we found that CTL from several donors recognize a peptide comprising 15 amino acids. The immune response against this peptide exerted by CTL lines from different donors was found to be restricted by two different molecules of the major histocompatibility complex: HLA-B8 and HLA-Cw6. The latter molecule could for the first time be identified as a restricting element for a CTL response. The epitope of the HLA-B8-restricted CTL could be mapped to an octameric sequence between amino acid positions 190 and 197 of the Zta protein, whereas the minimal epitope of HLA-Cw6-restricted CTL consists of 11 to 15 residues between positions 187 and 201. Thus, the HLA-B8 and HLA-Cw6 epitopes widely overlap but are not completely identical. In vitro stimulation of blood lymphocytes from a panel of HLA-B8-positive or HLA-Cw6-positive virus carriers, using autologous cells pulsed with the Zta peptides comprising the HLA-B8 or HLA-Cw6 epitope, respectively, revealed in both cases that most of these donors developed a Zta-specific cytotoxic activity. These data, as well as the high spread of the major histocompatibility complex molecules HLA-B8 and HLA-Cw6 in most populations, suggest that an efficient CTL response directed against gene products of the immediate-early group of the lytic cycle exists in vivo in a considerable portion of virus carriers. A CTL response against proteins expressed immediately after the switch into the lytic cycle could eliminate lytically activated cells at an early stage and would thus efficiently prevent the production and release of progeny virions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7609055      PMCID: PMC189301          DOI: 10.1128/JVI.69.8.4872-4879.1995

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.

Authors:  R Gavioli; M G Kurilla; P O de Campos-Lima; L E Wallace; R Dolcetti; R J Murray; A B Rickinson; M G Masucci
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

2.  Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth.

Authors:  N Lewin; P Aman; M G Masucci; E Klein; G Klein; B Oberg; H Strander; W Henle; G Henle
Journal:  Int J Cancer       Date:  1987-04-15       Impact factor: 7.396

3.  Transfection of a rearranged viral DNA fragment, WZhet, stably converts latent Epstein-Barr viral infection to productive infection in lymphoid cells.

Authors:  E Grogan; H Jenson; J Countryman; L Heston; L Gradoville; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

4.  Host immune response to cytomegalovirus: products of transfected viral immediate-early genes are recognized by cloned cytolytic T lymphocytes.

Authors:  U H Koszinowski; M J Reddehase; G M Keil; J Schickedanz
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

5.  Immunological function of HLA-C antigens in HLA-Cw3 transgenic mice.

Authors:  O Dill; F Kievits; S Koch; P Ivanyi; G J Hämmerling
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

6.  HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.

Authors:  S P Lee; W A Thomas; R J Murray; F Khanim; S Kaur; L S Young; M Rowe; M Kurilla; A B Rickinson
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

7.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.

Authors:  C J Barnstable; W F Bodmer; G Brown; G Galfre; C Milstein; A F Williams; A Ziegler
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

8.  Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells.

Authors:  M Rowe; D T Rowe; C D Gregory; L S Young; P J Farrell; H Rupani; A B Rickinson
Journal:  EMBO J       Date:  1987-09       Impact factor: 11.598

9.  A transcription factor with homology to the AP-1 family links RNA transcription and DNA replication in the lytic cycle of Epstein-Barr virus.

Authors:  A Schepers; D Pich; W Hammerschmidt
Journal:  EMBO J       Date:  1993-10       Impact factor: 11.598

10.  HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis.

Authors:  G Missale; A Redeker; J Person; P Fowler; S Guilhot; H J Schlicht; C Ferrari; F V Chisari
Journal:  J Exp Med       Date:  1993-03-01       Impact factor: 14.307

View more
  40 in total

1.  CD8(+) T-cell selection, function, and death in the primary immune response in vivo.

Authors:  M F Callan; C Fazou; H Yang; T Rostron; K Poon; C Hatton; A J McMichael
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

Review 2.  The immunology of Epstein-Barr virus infection.

Authors:  D J Moss; S R Burrows; S L Silins; I Misko; R Khanna
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

3.  Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: implications for molecular mimicry in autoimmune disease.

Authors:  I S Misko; S M Cross; R Khanna; S L Elliott; C Schmidt; S J Pye; S L Silins
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

4.  Hard wiring of T cell receptor specificity for the major histocompatibility complex is underpinned by TCR adaptability.

Authors:  Scott R Burrows; Zhenjun Chen; Julia K Archbold; Fleur E Tynan; Travis Beddoe; Lars Kjer-Nielsen; John J Miles; Rajiv Khanna; Denis J Moss; Yu Chih Liu; Stephanie Gras; Lyudmila Kostenko; Rebekah M Brennan; Craig S Clements; Andrew G Brooks; Anthony W Purcell; James McCluskey; Jamie Rossjohn
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-18       Impact factor: 11.205

5.  Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1.

Authors:  Barbara Adler; Eveline Schaadt; Bettina Kempkes; Ursula Zimber-Strobl; Barbara Baier; Georg W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

6.  Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.

Authors:  S Pepperl; G Benninger-Döring; S Modrow; H Wolf; W Jilg
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

7.  Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells.

Authors:  I V Redchenko; A B Rickinson
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

Review 8.  Role of donor versus recipient type Epstein-Barr virus in post-transplant lymphoproliferative disorders.

Authors:  T Haque; D H Crawford
Journal:  Springer Semin Immunopathol       Date:  1998

Review 9.  HLA-C revisited. Ten years of change.

Authors:  C S Falk; D J Schendel
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

10.  Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus.

Authors:  B M Kerr; N Kienzle; J M Burrows; S Cross; S L Silins; M Buck; E M Benson; B Coupar; D J Moss; T B Sculley
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.